Annual Review of Pharmacology and Toxicology

, volume 54 , issue 1 , pages 9-26

The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

Mathias Rask-Andersen ¹

Surendar Masuram ^{1, 2}

Helgi B. Schiöth ¹

Hide authors affiliations Show authors affiliations: 2 affiliations

Department of Neuroscience and Uppsala Biomedical Center, Uppsala University, 75124 Uppsala, Sweden; |

Uppsala Monitoring Center, 75140 Uppsala, Sweden |

Publication type: Journal Article

Publication date: 2014-01-06

Annual Reviews

Annual Review of Pharmacology and Toxicology

scimago Q1

wos Q1

SJR: 4.029

CiteScore: 27.4

Impact factor: 13.1

ISSN: 03621642, 15454304

DOI: 10.1146/annurev-pharmtox-011613-135943

Copy DOI

PubMed ID: 24016212

Pharmacology

Toxicology

Abstract

The largest innovations within pharmaceutical development come through new compounds that have unique and novel modes of action. These innovations commonly involve expanding the protein space targeted by pharmaceutical agents. At present, information about drugs and drug targets is available online via public databases such as DrugBank and the Therapeutic Targets Database. However, this information is biased, understandably so, toward established drugs and drug-target interactions. To gain a better overview of the drug-targeted portion of the human proteome and the directions of current drug development, we developed a data set of clinical trial drug-target interactions based on CenterWatch's Drugs in Clinical Trials Database, one of the largest databases of its kind. Our curation identified 475 potentially novel clinical trial drug targets. This review aims to identify trends in drug development based on the potentially novel targets currently being explored in clinical trials.

Found

Top-30

Journals

	1 2 3 4 5 6
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 6, 2.28% International Journal of Molecular Sciences 6 publications, 2.28%
Trends in Pharmacological Sciences	Trends in Pharmacological Sciences, 6, 2.28% Trends in Pharmacological Sciences 6 publications, 2.28%
Journal of Medicinal Chemistry	Journal of Medicinal Chemistry, 6, 2.28% Journal of Medicinal Chemistry 6 publications, 2.28%
Methods in Molecular Biology	Methods in Molecular Biology, 6, 2.28% Methods in Molecular Biology 6 publications, 2.28%
Oncotarget	Oncotarget, 5, 1.9% Oncotarget 5 publications, 1.9%
Frontiers in Pharmacology	Frontiers in Pharmacology, 5, 1.9% Frontiers in Pharmacology 5 publications, 1.9%
Molecular Pharmacology	Molecular Pharmacology, 4, 1.52% Molecular Pharmacology 4 publications, 1.52%
Nature Reviews Drug Discovery	Nature Reviews Drug Discovery, 4, 1.52% Nature Reviews Drug Discovery 4 publications, 1.52%
BMC Bioinformatics	BMC Bioinformatics, 4, 1.52% BMC Bioinformatics 4 publications, 1.52%
Pharmacological Research	Pharmacological Research, 4, 1.52% Pharmacological Research 4 publications, 1.52%
Chemical Reviews	Chemical Reviews, 4, 1.52% Chemical Reviews 4 publications, 1.52%
Nucleic Acids Research	Nucleic Acids Research, 4, 1.52% Nucleic Acids Research 4 publications, 1.52%
Annual Review of Pharmacology and Toxicology	Annual Review of Pharmacology and Toxicology, 4, 1.52% Annual Review of Pharmacology and Toxicology 4 publications, 1.52%
Scientific Reports	Scientific Reports, 3, 1.14% Scientific Reports 3 publications, 1.14%
Molecules	Molecules, 3, 1.14% Molecules 3 publications, 1.14%
PLoS ONE	PLoS ONE, 3, 1.14% PLoS ONE 3 publications, 1.14%
Current Opinion in Structural Biology	Current Opinion in Structural Biology, 3, 1.14% Current Opinion in Structural Biology 3 publications, 1.14%
Bioinformatics	Bioinformatics, 3, 1.14% Bioinformatics 3 publications, 1.14%
Current Topics in Medicinal Chemistry	Current Topics in Medicinal Chemistry, 2, 0.76% Current Topics in Medicinal Chemistry 2 publications, 0.76%
Current Medicinal Chemistry	Current Medicinal Chemistry, 2, 0.76% Current Medicinal Chemistry 2 publications, 0.76%
Current Drug Targets	Current Drug Targets, 2, 0.76% Current Drug Targets 2 publications, 0.76%
F1000Research	F1000Research, 2, 0.76% F1000Research 2 publications, 0.76%
Biochemical Society Transactions	Biochemical Society Transactions, 2, 0.76% Biochemical Society Transactions 2 publications, 0.76%
Cells	Cells, 2, 0.76% Cells 2 publications, 0.76%
Pharmaceutics	Pharmaceutics, 2, 0.76% Pharmaceutics 2 publications, 0.76%
Protein and Cell	Protein and Cell, 2, 0.76% Protein and Cell 2 publications, 0.76%
Nature Communications	Nature Communications, 2, 0.76% Nature Communications 2 publications, 0.76%
Nature Chemical Biology	Nature Chemical Biology, 2, 0.76% Nature Chemical Biology 2 publications, 0.76%
Biomedicine and Pharmacotherapy	Biomedicine and Pharmacotherapy, 2, 0.76% Biomedicine and Pharmacotherapy 2 publications, 0.76%
	1 2 3 4 5 6

Publishers

	10 20 30 40 50 60
Elsevier	Elsevier, 60, 22.81% Elsevier 60 publications, 22.81%
Springer Nature	Springer Nature, 45, 17.11% Springer Nature 45 publications, 17.11%
American Chemical Society (ACS)	American Chemical Society (ACS), 25, 9.51% American Chemical Society (ACS) 25 publications, 9.51%
Wiley	Wiley, 22, 8.37% Wiley 22 publications, 8.37%
MDPI	MDPI, 14, 5.32% MDPI 14 publications, 5.32%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 13, 4.94% Cold Spring Harbor Laboratory 13 publications, 4.94%
Oxford University Press	Oxford University Press, 11, 4.18% Oxford University Press 11 publications, 4.18%
Frontiers Media S.A.	Frontiers Media S.A., 9, 3.42% Frontiers Media S.A. 9 publications, 3.42%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 6, 2.28% Bentham Science Publishers Ltd. 6 publications, 2.28%
American Society for Pharmacology and Experimental Therapeutics	American Society for Pharmacology and Experimental Therapeutics, 5, 1.9% American Society for Pharmacology and Experimental Therapeutics 5 publications, 1.9%
Impact Journals	Impact Journals, 5, 1.9% Impact Journals 5 publications, 1.9%
Annual Reviews	Annual Reviews, 5, 1.9% Annual Reviews 5 publications, 1.9%
Taylor & Francis	Taylor & Francis, 4, 1.52% Taylor & Francis 4 publications, 1.52%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 4, 1.52% Public Library of Science (PLoS) 4 publications, 1.52%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 4, 1.52% American Association for the Advancement of Science (AAAS) 4 publications, 1.52%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 3, 1.14% American Society for Biochemistry and Molecular Biology 3 publications, 1.14%
F1000 Research	F1000 Research, 2, 0.76% F1000 Research 2 publications, 0.76%
Portland Press	Portland Press, 2, 0.76% Portland Press 2 publications, 0.76%
SAGE	SAGE, 2, 0.76% SAGE 2 publications, 0.76%
Institute of Electrical and Electronics Engineers (IEEE)	Institute of Electrical and Electronics Engineers (IEEE), 2, 0.76% Institute of Electrical and Electronics Engineers (IEEE) 2 publications, 0.76%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 0.38% Ovid Technologies (Wolters Kluwer Health) 1 publication, 0.38%
World Scientific	World Scientific, 1, 0.38% World Scientific 1 publication, 0.38%
Biophysical Society of China	Biophysical Society of China, 1, 0.38% Biophysical Society of China 1 publication, 0.38%
King Saud University	King Saud University, 1, 0.38% King Saud University 1 publication, 0.38%
Xi'an Jiaotong University	Xi'an Jiaotong University, 1, 0.38% Xi'an Jiaotong University 1 publication, 0.38%
American Medical Association (AMA)	American Medical Association (AMA), 1, 0.38% American Medical Association (AMA) 1 publication, 0.38%
Scientific Research Publishing	Scientific Research Publishing, 1, 0.38% Scientific Research Publishing 1 publication, 0.38%
eLife Sciences Publications	eLife Sciences Publications, 1, 0.38% eLife Sciences Publications 1 publication, 0.38%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 1, 0.38% American Society of Clinical Oncology (ASCO) 1 publication, 0.38%
	10 20 30 40 50 60

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

263

Cite this

GOST |

Cite this

GOST Copy

Rask-Andersen M. et al. The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication // Annual Review of Pharmacology and Toxicology. 2014. Vol. 54. No. 1. pp. 9-26.

GOST all authors (up to 50) Copy

Rask-Andersen M., Masuram S., Schiöth H. B. The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication // Annual Review of Pharmacology and Toxicology. 2014. Vol. 54. No. 1. pp. 9-26.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1146/annurev-pharmtox-011613-135943

UR - https://doi.org/10.1146/annurev-pharmtox-011613-135943

TI - The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

T2 - Annual Review of Pharmacology and Toxicology

AU - Rask-Andersen, Mathias

AU - Masuram, Surendar

AU - Schiöth, Helgi B.

PY - 2014

DA - 2014/01/06

PB - Annual Reviews

SP - 9-26

IS - 1

VL - 54

PMID - 24016212

SN - 0362-1642

SN - 1545-4304

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2014_Rask-Andersen,

author = {Mathias Rask-Andersen and Surendar Masuram and Helgi B. Schiöth},

title = {The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication},

journal = {Annual Review of Pharmacology and Toxicology},

year = {2014},

volume = {54},

publisher = {Annual Reviews},

month = {jan},

url = {https://doi.org/10.1146/annurev-pharmtox-011613-135943},

number = {1},

pages = {9--26},

doi = {10.1146/annurev-pharmtox-011613-135943}

}

MLA

Cite this

MLA Copy

Rask-Andersen, Mathias, et al. “The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication.” Annual Review of Pharmacology and Toxicology, vol. 54, no. 1, Jan. 2014, pp. 9-26. https://doi.org/10.1146/annurev-pharmtox-011613-135943.

Publisher

Annual Reviews

Journal

Annual Review of Pharmacology and Toxicology

scimago Q1

wos Q1

SJR

4.029

CiteScore

27.4

Impact factor

13.1

ISSN

03621642 (Print)

15454304 (Electronic)